Status:
COMPLETED
Mode of Action of Butyrate in the Human Colon
Lead Sponsor:
Örebro University, Sweden
Conditions:
Irritable Bowel Syndrome (IBS)
Healthy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Butyrate has recently gained attention as an important microbial compound in human colon health. Several diseases, including Irritable Bowel Syndrome (IBS), have been linked with a loss of butyrate in...
Eligibility Criteria
Inclusion
- signed informed consent
- Fulfilled Rome IV diagnostic criteria for IBS (for IBS participants)
Exclusion
- known gastrointestinal diseases
- previous complicated gastrointestinal surgery (including e.g. appendectomy or cholecystectomy)
- pregnancy or breast-feeding
- use of antibiotics within the last 12 weeks before the colonoscopy procedure
- regular consumption of probiotics within the last 4 weeks before the colonoscopy procedure
- use of laxatives or anti-diarrhoeals within the last 4 weeks before the colonoscopy procedure
- use of serotonin selective re-uptake inhibitors (SSRI) or serotonin nor-epinephrine re-uptake inhibitors (SNRI) with the last 12 weeks before the colonoscopy procedure
- alcohol or drug abuse
- latex allergy
- any other clinically significant disease/condition which in the investigator's opinion could interfere with the results of the study.
Key Trial Info
Start Date :
April 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 19 2021
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT05249023
Start Date
April 11 2018
End Date
February 19 2021
Last Update
February 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Örebro
Örebro, Örebro County, Sweden, 70185